Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Biosyngen to Establish Guangzhou-Singapore Translational Center for Cancer Drugs

publication date: Jul 12, 2023

Biosyngen, a cell and gene therapy company, announced plans to establish a Guangzhou-Singapore Technology Innovation and Translational Medicine Center for Tumor Prevention and Treatment. The goal of the Center is to attract both local and overseas therapeutic assets to incubate in the center and then support R&D of these assets. Biosyngen is dual-headquartered in Singapore and Guangzhou. The new Center is supported by the Guangzhou Knowledge City Investment Group  and Biosyngen. The company has two first-in-class products with approved INDs in the US and China and three more candidates in development. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital